Molecular Biological Mechanisms and Biomarkers of Multisystem Sequelae in Long COVID

Authors

  • Shan Jiang Department of Biology, Millersville University of Pennsylvania, Millersville, PA 17551, USA.

DOI:

https://doi.org/10.54097/599wwq46

Keywords:

Long COVID, Molecular Mechanisms, Biomarkers, Precision Medicine.

Abstract

With the prolonged evolution of SARS-CoV-2, the post-acute infection sequelae, widely recognized as Long COVID, has become a long-term challenge to global public health. Long COVID is a complex syndrome that affects multiple organs and systems; Its pathogenesis has not yet been fully clarified, and there is a lack of unified diagnostic and management strategies. This article provides a systematic review of the four core molecular biological mechanisms of Long COVID, and these include viral residuals, autoimmunity, microthrombosis, and reactivation of latent viruses. This review also looks into how these underlying molecular mechanisms are directly mapped to clinical multi-organ sequelae affecting the nervous, cardiovascular, and systemic and musculoskeletal. Building on this, the paper deeply summarizes the application value of cutting-edge biomarkers, for instance, plasma neurofilament light chain (NfL), thioflavin T fluorescence staining, and circulating cell-free mitochondrial DNA (ccf-mtDNA), and proposes a precision screening approach based on combined multi-biomarker testing. The significance of this study is to provide theoretical support for the public health system’s transition from empirical prevention and control to molecularly precise interventions. Future research could focus on standardized validation of potential biomarkers to establish a more stable biomarker detection system, thereby providing a more reliable theoretical basis for the early screening and precise intervention of Long COVID.

Downloads

Download data is not yet available.

References

[1] Davis HE, McCorkell L, Vogel JM, et al. Long COVID: major findings, mechanisms and recommendations. Nature Reviews Microbiology, 2023, 21:133–146. doi:10.1038/s41579-022-00846-2. DOI: https://doi.org/10.1038/s41579-022-00846-2

[2] Thaweethai T, Jolley SE, Karlson EW, et al. Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection. JAMA, 2023, 329(22):1934–1946. doi:10.1001/jama.2023.8823. DOI: https://doi.org/10.1001/jama.2023.8961

[3] Xie Y, Xu E, Bowe B, et al. Long-term cardiovascular outcomes of COVID-19. Nature Medicine, 2022, 28:583–590. doi:10.1038/s41591-022-01689-3. DOI: https://doi.org/10.1038/s41591-022-01689-3

[4] Stein SR, Ramelli SC, Grazioli A, et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature, 2022, 612:758–763. doi:10.1038/s41586-022-05542-y. DOI: https://doi.org/10.1038/s41586-022-05542-y

[5] Caliman-Sturdza OA, Hamamah S, Iatcu OC, et al. Microbiome and Long COVID-19: Current Evidence and Insights. International Journal of Molecular Sciences, 2025, 26(20):10120. doi:10.3390/ijms262010120. DOI: https://doi.org/10.3390/ijms262010120

[6] Kanberg N, Ashton NJ, Andersson LM, et al. Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19. Neurology, 2020, 95(12): e1754–e1759. doi:10.1212/WNL.0000000000010111. DOI: https://doi.org/10.1212/WNL.0000000000010111

[7] Turner S, Laubscher GJ, Khan MA, et al. Accelerating discovery: A novel flow cytometric method for detecting fibrin(ogen) amyloid microclots using long COVID as a model. Heliyon, 2023, 9(9): e19605. doi: 10.1016/j. heliyon. 2023.e19605. DOI: https://doi.org/10.1016/j.heliyon.2023.e19605

[8] Anang V, Kumar P, Pracha J, et al. SARS-CoV-2 innate immune recognition and implications for respiratory health. Cytokine & Growth Factor Reviews, 2025, 86:167–180. doi: 10.1016/j.cytogfr.2025.10.008. DOI: https://doi.org/10.1016/j.cytogfr.2025.10.008

[9] Wang EY, Mao T, Klein J, et al. Diverse functional autoantibodies in patients with COVID-19. Nature, 2021, 595:283–288. doi:10.1038/s41586-021-03631-y. DOI: https://doi.org/10.1038/s41586-021-03631-y

[10] Phetsouphanh C, Jacka B, Ballouz S, et al. Improvement of immune dysregulation in individuals with long COVID at 24-months following SARS-CoV-2 infection. Nature Communications, 2024, 15(1):3315. doi:10.1038/s41467-024-47720-8. DOI: https://doi.org/10.1038/s41467-024-47720-8

[11] Pretorius E, Vlok M, Venter C, et al. persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovascular Diabetology, 2021, 20(1):172. doi:10.1186/s12933-021-01359-7. DOI: https://doi.org/10.1186/s12933-021-01359-7

[12] Gold JE, Okyay RA, Licht WE, et al. Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation. Pathogens, 2021, 10(6):763. doi:10.3390/pathogens10060763. DOI: https://doi.org/10.3390/pathogens10060763

[13] Fernández-Castañeda A, Lu P, Geraghty AC, et al. Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation. Cell, 2022, 185(14):2452–2468.e16. doi: 10.1016/j.cell.2022.06.008. DOI: https://doi.org/10.1016/j.cell.2022.06.008

[14] Kavanagh E. Long Covid brain fog: a neuroinflammation phenomenon? Oxford Open Immunology, 2022, 3(1): iqac007. doi:10.1093/oxfimm/iqac007. DOI: https://doi.org/10.1093/oxfimm/iqac007

[15] Evans PC, Rainger GE, Mason JC, et al. Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science. Cardiovascular Research, 2020, 116(14):2177–2184. doi:10.1093/cvr/cvaa230. DOI: https://doi.org/10.1093/cvr/cvaa230

[16] Mancuso P, Gidaro A, Gregato G, et al. Circulating endothelial progenitors are increased in COVID-19 patients and correlate with SARS-CoV-2 RNA in severe cases. Journal of Thrombosis and Haemostasis, 2020, 18(10):2744–2750. doi:10.1111/jth.15044. DOI: https://doi.org/10.1111/jth.15044

[17] Yao S, Luo N, Liu J, et al. Elevated Serum Levels of Progranulin and Soluble Vascular Cell Adhesion Molecule-1 in Patients with COVID-19. Journal of Inflammation Research, 2021, 14:4785–4794. doi:10.2147/JIR.S330356. DOI: https://doi.org/10.2147/JIR.S330356

[18] Molnar T, Lehoczki A, Fekete M, et al. Mitochondrial dysfunction in long COVID: mechanisms, consequences, and potential therapeutic approaches. GeroScience, 2024, 46(5):5267–5286. doi:10.1007/s11357-024-01165-5. DOI: https://doi.org/10.1007/s11357-024-01165-5

[19] López-Hernández Y, Monárrez-Espino J, López DAG, et al. The plasma metabolome of long COVID patients two years after infection. Scientific Reports, 2023, 13(1):12420. doi:10.1038/s41598-023-39049-x. DOI: https://doi.org/10.1038/s41598-023-39049-x

[20] Szögi T, Borsos BN, Masic D, et al. Novel biomarkers of mitochondrial dysfunction in Long COVID patients. GeroScience, 2025, 47(2):2245–2261. doi:10.1007/s11357-024-01398-4. DOI: https://doi.org/10.1007/s11357-024-01398-4

Downloads

Published

15-11-2026

Issue

Section

Articles

How to Cite

Jiang, S. (2026). Molecular Biological Mechanisms and Biomarkers of Multisystem Sequelae in Long COVID. International Journal of Biology and Life Sciences, 17(2), 79-84. https://doi.org/10.54097/599wwq46